Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance-Reference-Cited by-同舟云学术

Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Grauers Wiktorin Hanna¹^ORCID,Aydin Ebru¹²^ORCID,Christenson Karin¹³^ORCID,Issdisai Nuttida¹^ORCID,Thorén Fredrik B.⁴^ORCID,Hellstrand Kristoffer¹^ORCID,Martner Anna¹^ORCID

Affiliation:

1. TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden

2. Molecular Genetics, Germany Cancer Research Center (DKFZ), Heidelberg, Germany

3. Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Sweden

4. TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden

Funder

Re:Mission Study Sponsor

Swedish Research Council

Swedish Society for Medical Research

Swedish State via the ALF agreement

Erna and Victor Hasselblad Foundation

Clas Groschinskys Memorial Foundation

Swedish Society of Medicine

Sahlgrenska Academy at University of Gothenburg

Publisher

Informa UK Limited

Subject